Buspirone for Opioid Tapering
CompletedPhase 1NCT03521960
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This is a pilot study to collect preliminary data to support a grant application. The goal of the study is to evaluate whether the Food and Drug Administration (FDA)-approved and generically-available medication buspirone reduces symptoms of opioid withdrawal among patients undergoing a clinically-indicated and supervised taper from their opioid pain medications. This is premised on strong preclinical scientific support but has not yet be well-examined in humans.
Study details
- Official title
- Buspirone as an Adjunctive Medication for Opioid Tapering
- Conditions
- Opioid-Related Disorders
- Dependency (Psychology)
- Pain, Chronic
- Opiate Withdrawal Syndrome
- Interventions
- Drug: Buspirone oral capsule
- Drug: Placebo oral capsule
- Sponsor
- Johns Hopkins University
- Start date
- 2018-05-30
- Primary completion
- 2020-06-30
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Be at least 18 years old * Be undergoing taper of prescribed opioid pain medications at the study site Exclusion Criteria: * Being pregnant or breastfeeding * Past 7-day use of grapefruit juice or other strong Cytochrome (CYP) P450 inhibitors or inducers * Have medical or psychiatric condition that is contraindicated with buspirone administration * Current suicidality as assessed by clinic staff or the Columbia Suicide Severity Rating Scale
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03521960